Isomorphic Labs closes $2.1B Series B led by Thrive Capital to push AlphaFold-derived drug design toward 2026 clinical trials

Isomorphic Labs, the DeepMind drug-discovery spinout founded in 2021, announced on May 12, 2026 that it has closed a $2.1 billion Series B led by Thrive Capital, with Alphabet, GV, MGX, Temasek, CapitalG, and the UK Sovereign AI Fund all participating. The round is one of the largest private financings ever for AI-led drug discovery and lifts Isomorphic’s cumulative funding to roughly $2.6 billion.

The capital is earmarked for IsoDDE, the company’s unified drug-design engine that extends AlphaFold’s protein-structure prediction into a single computational platform spanning protein-ligand interaction modeling, binding-affinity prediction, and binding-pocket identification. Isomorphic also maintains strategic discovery partnerships with Novartis, Eli Lilly, and Johnson & Johnson.

The target is first-in-human trials for AI-designed drugs by year-end 2026, a date that slipped from an earlier “by end of 2025” promise but is now backed by enough capital to fund the regulatory work.

Why this matters

AI drug discovery has been the most hyped frontier-AI vertical for three years and the slowest to produce ship-shaped product. AlphaFold itself is now embedded in nearly every structural-biology lab, but moving from structure prediction to a candidate that survives an FDA Phase I has been the field’s bottleneck. Isomorphic’s $2.1B round is the market’s bet that the bottleneck is finally about to break.

The investor list also says something specific about how the market is structuring AI biology:

• Thrive Capital leading signals that this is now a top-tier growth-equity asset, not a science-stage venture bet.
• Alphabet, GV, CapitalG all participating keeps Isomorphic firmly inside the Google orbit even as the round dilutes its position.
• MGX (Abu Dhabi) and the UK Sovereign AI Fund put sovereign capital onto the cap table. That is consistent with the broader 2026 pattern, sovereigns funding AI infrastructure and frontier biology as strategic assets, not just venture diversification.

For Novartis, Lilly, and J&J, this is the right kind of pressure. Their existing partnerships with Isomorphic are now backed by a balance sheet that can fund late-stage candidate development without forcing Isomorphic to license out at the asset level. That keeps the relationship a partnership rather than a vendor contract.

The slipped clinical timeline is the honesty in the announcement. AI drug discovery has burned credibility on aspirational timetables. Isomorphic explicitly resetting the human-trials target to end of 2026 instead of end of 2025 is the more credible posture; the $2.1B raise is the resource alignment to actually hit it.

Buyer take

If you run pharma BD or AI-strategy, three things to track from here:

• Watch which pipeline asset goes first. Isomorphic has not named the lead candidate publicly. The disease area, target class, and partnership status of the first IND filing will tell you more about IsoDDE’s real capability than any benchmark.
• Reassess your in-house AI biology stack. If Isomorphic’s platform reliably ships clinical candidates over the next 24 months, the build-vs-buy calculus for your internal AI-discovery teams shifts. Plan for a partnership-led posture, not just an internal capability buildout.
• Map the sovereign-capital angle. MGX and the UK Sovereign AI Fund participating signals that drug discovery is now in the same strategic-asset bucket as data centers and chip supply. Expect access negotiations to take on a national-security texture if Isomorphic’s program continues to hit.

For other AI biotech (Recursion, Insilico, Generate Biomedicines, Cradle Bio), the bar just moved. A $2.1B round at this stage redefines the funding-environment expectations for the field’s top tier.

What is still unclear

Isomorphic has not disclosed the post-money valuation, the lead disease area for the first IND filing, the structure of the new sovereign-capital allocations, or whether the Novartis, Lilly, and J&J partnerships have been re-priced as part of the financing. The split between internal pipeline development and platform-as-a-service for partners is also not described publicly.